期刊文献+

含多西他赛方案作为骨肉瘤二线化疗的疗效观察 被引量:5

Clinical observation of docetaxel based regimens as the second-line chemotherapy in osteosarcoma
下载PDF
导出
摘要 目的探讨含多西他赛方案二线治疗一线化疗失败的骨肉瘤肺转移患者的有效性和安全性。方法收集2012年1月至2013年12月间我科收治的11例一线化疗失败的骨肉瘤肺转移患者,给予多西他赛(75 mg/m2,d8)联合吉西他滨(675 mg/m2,d1、d8)/洛铂(30 mg/m2,d2)方案二线化疗,21天为1周期,共化疗6个周期。采用RECIST标准1.0版评价疗效,NCI-CTC标准3.0版观察不良反应。结果 11例患者均完成化疗,可评价疗效。无完全缓解(CR)病例,部分缓解(PR)1例,疾病稳定(SD)4例,疾病进展(PD)6例;有效率(RR)为9.1%,疾病控制率(DCR)为45.5%。随访6~23个月,3例死亡。中位无进展生存时间为10.5个月,中位生存时间为18.0个月,1年生存率为83.3%。主要不良反应为限制性骨髓抑制,化疗期间患者无明显肾功能异常及过敏反应,仅出现4级中性粒细胞及血小板减少1例。结论含多西他赛方案二线治疗骨肉瘤肺转移,近期疗效满意,毒副反应可以耐受。 Objective To investigate the efficacy and side effects of docetaxel based regimens as the second-line chemothera-py in osteosarcoma with lung metastasis.Methods From January 2012 to December 2013, 11 osteosarcoma patients with lung metasta-sis whom failed from first-line chemotherapy were taken docetaxel(75 mg/ m2, d8) combined with gemcitabine(675 mg/ m2, d1, d8) /platinum(30 mg/ m2, d2) as the second-line chemotherapy. 21 days was a cycle. The first-line chemotherapy contained cisplatin, ifos-famide, adriamycin methotrexate alternating scheme. The efficacy was evaluated by RECIST 1. 0 criterion, and side effects were recor-ded by NCI-CTC 3. 0 criterion.Results All patients finished treatment, and could be evaluated. There was no complete remission(CR) case, partial remission(PR) in 1 case, stable disease(SD) in 4 cases, progression of disease(PD) in 6 cases; and the re-sponse rate(RR) was 9. 1%, disease control rate(DCR) was 45. 5%. During the follow-up period, 3 patients died. The median pro-gression free survival time was 10. 5 months, the median overall survival time was 18. 0 months, and 1-year survival rate was 83. 3%.The major adverse reactions were limiting myelosuppression during chemotherapy. There was no patients with renal dysfunction and al-lergic reaction, grade 4 neutropenia and thrombocytopenia was occured in 1 case.Conclusion Docetaxel based regimen is effective asthe second-line chemotherapy in osteosarcoma with lung metastasis, and the short-term curative effect is satisfactory, toxicity can betolerated.
出处 《临床肿瘤学杂志》 CAS 2015年第2期155-159,共5页 Chinese Clinical Oncology
关键词 多西他赛 骨肉瘤 肺转移 二线化疗 Docetaxel Osteosarcoma Pulmonary metastasis Second-line chemotherapy
  • 相关文献

参考文献24

  • 1Liu ZL, Wang G, Peng AF, et al. Fatty acid synthase expressionin osteosarcoma and its correlation with pulmonary metastasis[ J].Oncol Lett, 2012,4(5) :878-882.
  • 2汤国庆,燕太强,郭卫,杨荣利,彭长亮,赵会.骨肉瘤肺转移相关基因的最新研究进展[J].中国骨肿瘤骨病,2010,9(4):368-372. 被引量:7
  • 3Lamb S,Reavill D,Wojcieszyn J,et al. Osteosarcoma of the tib-iotarsus with possible pulmonary metastasis in a ring-necked dove(Streptopelia risoria) [ J] . J Avian Med Surg,2014,28 ( 1 ) : 50-56.
  • 4牛晓辉,王洁.经典型骨肉瘤诊断与治疗路径[J].中国骨肿瘤骨病,2010(2):97-100. 被引量:8
  • 5Mebarki M,Medjahedi A, Menemani A, et al. Osteosarcomapulmonary metastasis mimicking abnormal skeletal uptake in bonescan: utility of SPECT/CT[ J]. Clin Nucl Med, 2013,38(10):e392-e394.
  • 6Taylor PT, Haverstick D. Re; New guidelines to evaluate the re-sponse to treatment in solid tumors ( ovarian cancer) [ J]. J NatlCancer Inst, 2005,97(2) :152.
  • 7Thompson RJ, Cheng EY,Clohisy DR, et al. Results oftreatment for metastatic osteosarcoma with neoadjuvant chemother-apy and surgery [ J ] . Clin Orthop Relat Res,2002 ’ 397 : 240-247.
  • 8Letoumeau PA, Xiao L, Halting MT, et al. Location ofpulmonary metastasis in pediatric osteosarcoma is predictive ofoutcome[ J] . J Pediatr Surg, 2011,46(7) : 1333-1337.
  • 9牛晓辉,杨勇昆,黄真,徐海荣.白蛋白结合型紫杉醇二线治疗骨肉瘤肺转移的临床观察[J].临床肿瘤学杂志,2013,18(2):114-116. 被引量:4
  • 10杨迪生,李伟栩,陶惠民,叶招明,柴莹.骨肉瘤肺转移的诊断和治疗近况[J].中华骨科杂志,2000,20(B12):68-70. 被引量:8

二级参考文献82

  • 1郭卫,汤小东,唐顺,杨毅.三氧化二砷联合化疗治疗Ⅲ期成骨肉瘤、尤文肉瘤的初步报告[J].中华外科杂志,2006,44(12):805-808. 被引量:26
  • 2Khanna C,Khan J,Nguyen P,et al.Metastasis-associated differences in gene expression in a murine model of osteosarcoma.Cancer Res,2001,61:3750-3759.
  • 3Leonard P,Sharp T,Henderson S,et al.Gene expression array profile of human osteosarcoma.Br J Cancer,2003,89:2284-2288.
  • 4Nakano T,Tani M,Ishibashi Y,et al.Biological properties and gene expression associated with metastatic potential of human osteosarcoma.Clin Exp Metastasis,2003,20:665-674.
  • 5Srivastava A,Fuchs B,Zhang KB,et al.High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis.Clin Cancer Res,2006,12:4237-4243.
  • 6Dalla-Torre CA,Yoshimoto M,Lee CH,et al.Effects of THBS3,SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma.BMC Cancer,2006,6:237-247.
  • 7Scotlandi K,Manara M,Hattinger CM,et al.Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.Eur J Cancer,2005,41:1349-61.
  • 8Lee WI,Bacchni P,Bertoni F,et al.Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma.Onco rep,2004,12:125-128.
  • 9Gorlick R,Huvos AG,Heller G,et al.Expression of HER2/erbB-2 correlates with survival in osteosarcoma.J Clin Oncol,1999,17:2781-2788.
  • 10Kim MS,Song WS,Cho WH,et al.Ezrin expression predicts survival in stage II B osteosarcomas.Clin Orthop and Relate Res,2007,459:229-236.

共引文献31

同被引文献47

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部